Clearside Biomedical Inc (NASDAQ: CLSD)’s stock price has increased by 12.39 compared to its previous closing price of 1.13. However, the company has seen a 32.29% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-27 that – CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector ® –
Is It Worth Investing in Clearside Biomedical Inc (NASDAQ: CLSD) Right Now?
The stock has a 36-month beta value of 2.30. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLSD is 63.26M, and at present, short sellers hold a 0.28% of that float. On September 11, 2024, the average trading volume of CLSD was 209.87K shares.
CLSD’s Market Performance
The stock of Clearside Biomedical Inc (CLSD) has seen a 32.29% increase in the past week, with a 18.69% rise in the past month, and a 1.60% gain in the past quarter. The volatility ratio for the week is 7.57%, and the volatility levels for the past 30 days are at 5.82% for CLSD. The simple moving average for the past 20 days is 25.14% for CLSD’s stock, with a 0.87% simple moving average for the past 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with Chardan Capital Markets repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on August 21, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $5. The rating they have provided for CLSD stocks is “Outperform” according to the report published on June 25th, 2024.
Wedbush gave a rating of “Outperform” to CLSD, setting the target price at $9 in the report published on December 15th of the previous year.
CLSD Trading at 14.67% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.09% of loss for the given period.
Volatility was left at 5.82%, however, over the last 30 days, the volatility rate increased by 7.57%, as shares surge +11.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.03% lower at present.
During the last 5 trading sessions, CLSD rose by +23.96%, which changed the moving average for the period of 200-days by +19.00% in comparison to the 20-day moving average, which settled at $1.0211. In addition, Clearside Biomedical Inc saw 8.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLSD starting from Chong Ngai Hang Victor, who purchase 23,500 shares at the price of $1.06 back on Jun 24 ’24. After this action, Chong Ngai Hang Victor now owns 63,500 shares of Clearside Biomedical Inc, valued at $24,910 using the latest closing price.
YERXA BENJAMIN R, the Director of Clearside Biomedical Inc, purchase 7,813 shares at $1.31 during a trade that took place back on May 15 ’24, which means that YERXA BENJAMIN R is holding 17,957 shares at $10,235 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -3.42 for the present operating margin
- 0.97 for the gross margin
The net margin for Clearside Biomedical Inc stands at -4.45. The total capital return value is set at -0.92. Equity return is now at value -1310.02, with -91.51 for asset returns.
Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated 2.5 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at -1.67. The interest coverage ratio of the stock is -5.86.
Currently, EBITDA for the company is -24.78 million with net debt to EBITDA at -1.14. When we switch over and look at the enterprise to sales, we see a ratio of 16.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.07.
Conclusion
To sum up, Clearside Biomedical Inc (CLSD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
